RegeneRx Pipeline

RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology.

RegeneRx acquired the rights to a novel peptide from the NIH in 1999. This intellectual property for Thymosin Beta 4 (Tβ4) allowed the company to direct its focus on tissue protection and repair in multiple disease indications.

Learn More

Latest News
May 2, 2018

ReGenTree, LLC (the "Company"), a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals (OTCQB: RGRX), announced today that the Company presented results of a comparison study of RGN-259...

Apr 25, 2018

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today is informing...

More >

print email